Recent Finacing
Recent Raise
Autobahn Therapeutics is a San Diego–based biotech developing brain‑targeting small‑molecule CNS therapeutics, including TRβ agonist ABX‑002 and CNS‑penetrant S1P modulator ABX‑101, advancing into clinical trials for depression, remyelination, and neuroinflammation.
